GHK-Cu + Thymosin Alpha-1 Stack: Safety, Monitoring, and Dosing Protocol

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Is the GHK-Cu and thymosin alpha-1 stack approved?

No. No FDA-approved drug contains GHK-Cu; FDA treats it as a nominated bulk drug substance, not an approved medicine [1]. Copper histidinate (Zycubo), which FDA approved in January 2026 for Menkes disease in children, is a different compound [9]. Thymosin alpha-1 (thymalfasin) has no US application; FDA's December 2024 review notes four US orphan drug designations, and orphan designation is a separate process from approval [2]. Compounded products of either peptide are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [10].

What each peptide is and what it is reported to do

GHK-Cu is the copper(II) complex of GHK, a tripeptide found in human plasma, saliva and urine whose levels are reported to decline with age [11]. Its proposed actions — stimulating collagen and proteoglycan production, modulating metalloproteinases, attracting immune and endothelial cells to injury, and faster wound healing in dogs, rats, mice and pigs — come from laboratory and animal work summarized by the researchers who proposed them, not from proven human effects [11].

Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5; thymalfasin is the synthetic version with the same sequence [2]. Zadaxin, the finished injection sold outside the US, is not interchangeable with bulk thymosin alpha-1 powder [2]. Thymosin alpha-1 is described as an immune modulator that augments T-cell function [7]. A 2007 review of laboratory and animal work describes it acting on dendritic cells through Toll-like receptor signaling, including plasmacytoid dendritic cells via TLR9 [12]. After subcutaneous injection in healthy volunteers it peaks at about 0.7 to 2 hours and clears with a half-life of about 1.8 to 2.6 hours, with no accumulation after daily dosing for five days [7][2].

Dosing: what a label or a trial actually supports

GHK-Cu has no FDA-approved drug or dose, and topical cosmetic strengths are set by manufacturers and are not FDA-reviewed [1][13]. The drug-style human trial used a 0.4% tripeptide copper complex cream, and it was no different from an inert vehicle for ulcer size in 86 evaluable patients with venous stasis ulcers, while silver sulfadiazine 1% did reduce ulcer size [3]. In the other randomized trial, 13 patients had circumoral skin resurfaced with a CO2 laser and then used skin care with or without GHK-Cu: computer analysis and blinded evaluators found no significant difference in redness resolution, wrinkles or overall skin quality, while the patient questionnaire favored GHK-Cu for overall skin quality (P=.04) [8]. A 2026 systematic review of the GHK-Cu literature kept 64 records and concluded the human literature is thin and fragmented, with microneedle delivery never tested in a single registered, adequately powered human randomized trial [14]. We do not list injection doses here.

Thymosin alpha-1 has no US-approved dose. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination; the label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [2]. That is one country's product label schedule, not a US-approved regimen.

Safety: what FDA and the labels flag

For injectable GHK-Cu, FDA's stated concern is immunogenicity risk from the potential for aggregation and peptide-related impurities, with limited human data to inform safety considerations [5]. For thymosin alpha-1, FDA cited significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [5].

An FDA search of its adverse-event database in April 2024 found zero reports for thymosin alpha-1 [2]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as infrequent and mild; that is company-linked data [2]. A 2026 Cochrane review of 10 randomized hepatitis B trials (1,349 adults) found thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [15]. The same reviewers said they are not sure thymosin alpha-1 helps in hepatitis B [15].

For topical GHK-Cu products, no adverse-event rates were found in the trials checked [5].

Regulatory status and compounding

Non-injectable GHK-Cu, such as topical products, sits in category 1 on FDA's list for state-licensed pharmacies and physicians, the group under evaluation for the bulks list; FDA says it generally does not intend to act against compounders of category 1 substances if the conditions in its guidance are met [1][4]. Injectable GHK-Cu is in FDA's nominated but withdrawn table, is not in category 1, and is in no category on the current list [5][1]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether to include GHK-Cu on the bulks list, and no vote has happened yet [1].

Thymosin alpha-1 is in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and it is in category 3, nominated without adequate support, on FDA's list for outsourcing facilities [1][6]. FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate on December 4, 2024 [16]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [17].

A topical copper peptide serum or cream is generally a cosmetic: cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, but claims to treat disease or change the body's structure or function make a product a drug [13]. HealthRX.com's copper peptide cream is listed for reference; no GHK-Cu drug is FDA-approved.

Neither peptide is named on WADA's 2026 or 2027 Prohibited List, although WADA's notes say peptides not specifically named may still be prohibited, so athletes should check with their anti-doping organization [18][19].